Iberdomide
Iberdomide 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Myeloma、Multiple Myeloma、Refractory Multiple Myeloma。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
16 项
全球在招研究
2 项
已进入 III/IV 期
13 个
开展国家和地区
暂未检索到
中国境内设点
药品与企业信息
研发企业
- Omar Nadeem, MD
- Benjamin T Diamond, MD
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- AbbVie
- Barbara Ann Karmanos Cancer Institute
- National Cancer Institute (NCI)
- Mayo Clinic
- Alfred Chung, MD
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
美国、加拿大、澳大利亚、法国、日本、荷兰、挪威、Israel、英国、德国、Poland、South Korea
正在招募患者的 Iberdomide 研究
Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma
II 期招募中美国NCT05896228A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
I 期招募中美国加拿大NCT06121843Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
I 期招募中美国澳大利亚加拿大法国NCT06896916Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
I 期 / II 期招募中美国NCT06518551Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma
II 期招募中美国NCT06107738Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
I 期招募中美国NCT06465316Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma
I 期 / II 期招募中美国NCT06785415A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
I 期 / II 期招募中美国澳大利亚Israel日本NCT06892522Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
I 期招募中美国NCT06348108Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma
II 期招募中美国NCT04776395A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma
I 期 / II 期招募中澳大利亚法国德国PolandNCT05583617D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM
III 期招募中美国NCT07624513Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse
I 期 / II 期招募中美国NCT07437963Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients
II 期招募中加拿大NCT05272826Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma
II 期招募中英国NCT06762769NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide
III 期招募中西班牙NCT05558319
中国患者怎么争取用上这款药
目前境内暂未检索到设点，下面几条途径是更现实的选择，每条都有详细的中文做法。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。